Fig. 7From: Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding propertiesFcRn binding properties determined by ELISA. (a) No binding of faricimab to human FcRn at pH 5.5. Bevacizumab functions as positive control. (b) No binding of either faricimab or bevacizumab at pH 7.4. Each data point represents the mean of a duplicate point on the ELISA plateBack to article page